Clinicopathological factors vs. molecular model for predicting adjuvant EGFR-TKI benefit in stage I EGFR-mutant non-small cell lung cancer
The 14-gene assay is proven to be superior to clinicopathological factors, offering valuable guidance for adjuvant EGFR-TKIs decisions in stage I NSCLC.
Authors
- Caichen Li (ORCID: https://orcid.org/0000-0001-5434-1722)
- Hengrui Liang (ORCID: https://orcid.org/0000-0002-1155-5963)
- Ran Cheng (ORCID: https://orcid.org/0000-0002-7617-3018)
- Wenhai Fu
- Songan Chen
- Ran Zhong (ORCID: https://orcid.org/0000-0001-6840-2661)
- Bingliang Li
- Wei Wang (ORCID: https://orcid.org/0000-0001-5161-8175)
- Jianxing He (ORCID: https://orcid.org/0000-0003-1737-8192)
- Shan Xiong (ORCID: https://orcid.org/0000-0001-5271-2825)
- Hongsheng Deng (ORCID: https://orcid.org/0000-0003-4886-0889)
- Yu Jiang (ORCID: https://orcid.org/0000-0002-2443-911X)
- Jianfu Li (ORCID: https://orcid.org/0009-0004-9378-8462)
- Wenhua Liang (ORCID: https://orcid.org/0000-0002-8159-7720)
- Yuechun Lin (ORCID: https://orcid.org/0009-0004-8855-8355)
- Zhexue Hao
- Si Jiang
- Qihua He
Institutions
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Burning Rock Biotech (China) (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.21037/tlcr-2025-20
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52